A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Bleomycin
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ECT_PEMBRO
Most Recent Events
- 20 Sep 2024 According to ClinicalTrials.gov: US National Institutes of Health , this trial has been withdrawn due to no financial support
- 20 Sep 2024 Status changed from recruiting to discontinued.
- 27 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2023.